{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T18:39:59Z","timestamp":1785004799556,"version":"3.55.0"},"reference-count":30,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    CD19\u2010targeted chimeric antigen receptor (CAR) T\u2010cell therapy has revolutionized treatment for patients with relapsed\/refractory large B\u2010cell lymphoma (LBCL). However, data available concerning the impact of the prognostic value of quantitative 18F\u2010fluorodeoxyglucose positron emission tomography\u2010computed tomography (FDG PET\/CT) parameters on the CAR T\u2010related outcomes and toxicities are limited. Therefore, we aimed to evaluate the predictive value of pre\u2010 and post\u2010CAR T metabolic parameters on survival and toxicities following CAR T\u2010cell therapy. Fifty\u2010nine patients with PET\/CT scans done pre\u2010and post\u2010CAR T infusion were retrospectively identified and analyzed in a single institution database of LBCL patients treated with commercial CD19\u2010targeted CAR T\u2010cell therapy. The median follow\u2010up was 10.7\u00a0months [interquartile range (IQR): 2.6\u201325.5\u00a0months]. The overall response (complete response\u2010CR and partial response) and CR rates post\u2010CAR T were 76% (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a045) and 53% (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a031), respectively. On univariate analysis, low pre\u2010CAR T total lesion glycolysis (TLG) and metabolic tumor volume (MTV) predicted improved overall response post\u2010CAR T (OR\u00a0=\u00a04.7,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.01, OR\u00a0=\u00a09.5,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.03, respectively) and CR post\u2010CAR T (OR\u00a0=\u00a012.4,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.0004, OR\u00a0=\u00a010.9,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.0001, respectively). High TLG pre\u2010CAR T was correlated with cytokine release syndrome (CRS, OR\u00a0=\u00a03.25,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.04). High MTV pre\u2010CAR T was correlated with developing immune effector cell neurotoxicity syndrome (ICANS) events (OR\u00a0=\u00a04.3,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.01), and high SUV pre\u2010CAR T was associated with grade 3\u20134 neurological events (OR\u00a0=\u00a012,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.01). High MTV\/TLG\/SUVmax post\u2010CAR T were significantly associated with inferior Overall survival (OS). On multivariate analysis, high TLG pre\u2010CAR T (HR\u00a0=\u00a02.4,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.03), age \u226560 (HR\u00a0=\u00a02.7,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.03), and bulky disease (\u22655\u00a0cm) at the time of apheresis (HR\u00a0=\u00a02.5,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.02) were identified to be independent prognostic factors for inferior PFS. High MTV post\u2010CAR T was identified as the most prognostic factor associated with inferior OS.\n                  <\/jats:p>","DOI":"10.1002\/hon.3231","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T06:42:41Z","timestamp":1696488161000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Metabolic parameters predict survival and toxicity in chimeric antigen receptor T\u2010cell therapy\u2010treated relapsed\/refractory large B\u2010cell lymphoma"],"prefix":"10.1002","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0393-9852","authenticated-orcid":false,"given":"Hazim S.","family":"Ababneh","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology Massachusetts General Hospital Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea K.","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Brigham and Women's Hospital, Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy S.","family":"Abramson","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Massachusetts General Hospital Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob D.","family":"Soumerai","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Massachusetts General Hospital Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald W.","family":"Takvorian","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Massachusetts General Hospital Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Frigault","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Massachusetts General Hospital Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirayu G.","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Massachusetts General Hospital Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,10,5]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1707447"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1804980"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(20)31366\u20100"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2116133"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2022.08.007"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/CNCR.27855"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD\u20102014\u201012\u2010616474"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.9440"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/S00259\u2010016\u20103315\u20107"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201015\u20102825"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.18632\/ONCOTARGET.13180"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD\u20102016\u201010\u2010744292"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.2967\/JNUMED.117.193946"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD\u20102017\u201007\u2010795476"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/S00259\u2010017\u20103907\u2010X"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0210224"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJCA.2019.09.027"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2019003526"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/BLOODADVANCES.2019001201"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.4143\/CRT.2020.123"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02063"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.BBMT.2019.02.008"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/BLOODADVANCES.2020001900"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000003756"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2022.834288"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/BLOODADVANCES.2021005807"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/HON.2965"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/BLOODADVANCES.2020002394"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.05.014"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102014\u201005\u2010552729"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.3231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T11:07:59Z","timestamp":1711451279000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.3231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,5]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1002\/hon.3231"],"URL":"https:\/\/doi.org\/10.1002\/hon.3231","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/HON.3231\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.3231\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.3231\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.3231\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.3231\/v1\/decision1","asserted-by":"object"}]},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,5]]},"assertion":[{"value":"2023-06-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e3231"}}